S6196

Simvastatin

≥97% (HPLC), solid

• Synonim(y): MK-733, SVA
• Wzór empiryczny (zapis Hilla): C₂₅H₃₈O₅
• Numer CAS: 79902-63-9
• Masa cząsteczkowa: 418.57
• Numer MDL: MFCD00072007
• Kod UNSPSC: 12352200
• Identyfikator substancji w PubChem: 24724617
• NACRES: NA.77

Właściwości

• Poziom jakości: 100
• Próba: ≥97% (HPLC)
• Formularz: solid
• kolor: white
• mp: 127-132 °C (lit.)
• rozpuszczalność: DMSO: ≥20 mg/mL
• inicjator: Merck & Co., Inc., Kenilworth, NJ, U.S.
• temp. przechowywania: 2-8°C
• ciąg SMILES: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC
• InChI: 1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
• Klucz InChI: RYMZZMVNJRMUDD-HGQWONQESA-N
• informacje o genach: human ... HMGCR(3156) ; rat ... Hmgcr(25675)

Opis

Opis ogólny

Simvastatin is a prodrug. Simvastatin is a semisynthetic derivative/analog of lovastatin. Simvastatin is insoluble in water but is soluble in polar organic solvents.

Zastosowanie

Simvastatin has been used:

• as an inhibitor of HMG CoA reductase (HMGCR)
• to study its effects on epithelial to mesenchymal transition (EMT) and the prognosis of patients with lung adenocarcinoma
• in in vivo studies to test its effect on brain tumor−initiating cells (BTIC) viability and cell proliferation
• to study the role of adenosine triphosphate (ATP)-binding cassette transporter A7 in phagocytosis of Jurkat cells
• to study the effect on endothelial dysfunction and inflammation in mice

Działania biochem./fizjol.

Simvastatin is a specific inhibitor of HMG-CoA reductase and cholesterol lowering drug.

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins cholesterol and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid and can be activated prior to use with NaOH in EtOH treatment. It may also have beneficial effects on endothelial function, inflammation, smooth muscle cell function, vascular wall function, hemostasis and LDL oxidation.

Cechy i korzyści

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS08
• Hasło ostrzegawcze: Warning
• Zwroty wskazujące rodzaj zagrożenia: H361d
• Zwroty wskazujące środki ostrożności: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Klasyfikacja zagrożeń: Repr. 2
• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable
• Środki ochrony indywidualnej: Eyeshields, Gloves, type N95 (US)